← All trials
NCT05709288
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 23, 2023
- Primary completion
- Jun 30, 2035
- Completion date
- Nov 30, 2035
- First posted
- Feb 2, 2023
- Last posted
- Nov 24, 2023
- Enrollment
- 9
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China Academy of Chinese Medical SciencesLead sponsor
- China Academy of Chinese Medical SciencesReponsible party - principal investigator
- China Academy of Chinese Medical SciencesSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.